GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence
Summary Background Subjects with non‐functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy. The safety of GH replacement (GHR) in these individuals remains unclear. Objective To assess the effect of GHR on tumour recurr...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2009-03, Vol.70 (3), p.435-438 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 438 |
|---|---|
| container_issue | 3 |
| container_start_page | 435 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 70 |
| creator | Arnold, J. R. Arnold, D. F. Marland, A. Karavitaki, N. Wass, J. A. H. |
| description | Summary
Background Subjects with non‐functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy. The safety of GH replacement (GHR) in these individuals remains unclear.
Objective To assess the effect of GHR on tumour recurrence in patients with NFAs solely treated by surgical removal.
Patients and methods The study involved all patients with NFA who presented to the Department of Endocrinology in Oxford between January 1989 and July 2005 and were treated solely by surgical removal of the tumour. Patients with follow up |
| doi_str_mv | 10.1111/j.1365-2265.2008.03391.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66954046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20402974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4661-b7a7a61e426bf4c8acc3ff0fdbf33c17b640e452b0bc241918589f3bce0d59f13</originalsourceid><addsrcrecordid>eNqNkc2O0zAUhSMEYsrAKyBvQLBIuP6JkyxYjKqZDlJVNiCWluPYgzuJU2xH074LD4vTVmUJ3vja_s7xtU-WIQwFTuPTtsCUlzkhvCwIQF0ApQ0u9s-yxeXgebYACpAD5-wqexXCFgDKGqqX2RVuCE3bsMh-r-6R17teKj1oF5F1aCejTWVATzb-RG50uZmcinZ01j2gnY2TjdIfkOy0GweJPmzubj6i6LWMukNh7HV_QO0Bhck_6MTZkEwikiGMyh6Zo7F1KklCWnobHtFoUJyGcfKpHTV5r53Sr7MXRvZBvznP19n3u9tvy_t8_XX1ZXmzzhXjHOdtJSvJsWaEt4apWipFjQHTtYZShas2vVSzkrTQKsJwg-uybgxtlYaubAym19n7k-_Oj78mHaIYbFC676XT4xQE503JgPF_ggQYkKZiCaxPoPJjCF4bsfN2SL8mMIg5QrEVc1JiTkrMEYpjhGKfpG_Pd0ztoLu_wnNmCXh3BmRQsjdeOmXDhSMY04bwmft84p5srw__3YBY3m7mKunzk96GqPcXvfSPgle0KsWPzUow3kBTrkHU9A_ousj-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20402974</pqid></control><display><type>article</type><title>GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Arnold, J. R. ; Arnold, D. F. ; Marland, A. ; Karavitaki, N. ; Wass, J. A. H.</creator><creatorcontrib>Arnold, J. R. ; Arnold, D. F. ; Marland, A. ; Karavitaki, N. ; Wass, J. A. H.</creatorcontrib><description>Summary
Background Subjects with non‐functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy. The safety of GH replacement (GHR) in these individuals remains unclear.
Objective To assess the effect of GHR on tumour recurrence in patients with NFAs solely treated by surgical removal.
Patients and methods The study involved all patients with NFA who presented to the Department of Endocrinology in Oxford between January 1989 and July 2005 and were treated solely by surgical removal of the tumour. Patients with follow up < 1 year were excluded. Recurrence was diagnosed on the basis of radiological appearances (detectable tumour after gross total removal or regrowth of pre‐existing residue) on regular imaging surveillance.
Results One hundred and thirty patients were included in the study, and were followed up for a mean period of 6·8 ± 4·2 years (median 5·7, range 1·2–17·6). Twenty‐three patients received GHR [16 male, 7 female, mean age at tumour diagnosis 53·7 ± 14·6 years (range 20–80)]. The mean duration of GHR was 4·6 ± 2·5 years (median 5·3, range 0·4–8·7). One hundred and seven subjects did not receive GH therapy [61 male, 46 female, mean age at tumour diagnosis 56·2 ± 14·0 years (range 20–87)]. Tumour regrowth occurred in 38 non‐GH treated subjects (36%) and 8 GHR subjects (35%). Regrowth was detected at a mean of 4·8 ± 2·8 years (range 1–11 years) in the non‐GH treated group, and at 6·5 ± 2·3 years in the GHR group. In the GHR group, recurrence occurred after a mean of 2·9 ± 2·2 years (range 0·4–5·9 years) following commencement of GH treatment. The Cox regression analysis showed that after adjusting for sex, age at tumour diagnosis, cavernous sinus invasion at diagnosis and type of tumour removal (partial or complete based on postoperative scan), GH treatment was not a significant independent predictor of recurrence (P = 0·09; hazard ratio = 0·51; 95% CI, 0·24–1·12).
Conclusion GH replacement in patients with NFA treated by surgery alone is not associated with an increased risk of tumour recurrence.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/j.1365-2265.2008.03391.x</identifier><identifier>PMID: 19236640</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adenoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Endocrinopathies ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Growth Hormone - adverse effects ; Growth Hormone - deficiency ; Growth Hormone - therapeutic use ; Humans ; Hypothalamus. Hypophysis. Epiphysis (diseases) ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - epidemiology ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Pituitary Neoplasms - surgery ; Regression Analysis ; Retrospective Studies ; Risk Factors ; Vertebrates: endocrinology</subject><ispartof>Clinical endocrinology (Oxford), 2009-03, Vol.70 (3), p.435-438</ispartof><rights>2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4661-b7a7a61e426bf4c8acc3ff0fdbf33c17b640e452b0bc241918589f3bce0d59f13</citedby><cites>FETCH-LOGICAL-c4661-b7a7a61e426bf4c8acc3ff0fdbf33c17b640e452b0bc241918589f3bce0d59f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2265.2008.03391.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2265.2008.03391.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21139260$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19236640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arnold, J. R.</creatorcontrib><creatorcontrib>Arnold, D. F.</creatorcontrib><creatorcontrib>Marland, A.</creatorcontrib><creatorcontrib>Karavitaki, N.</creatorcontrib><creatorcontrib>Wass, J. A. H.</creatorcontrib><title>GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Summary
Background Subjects with non‐functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy. The safety of GH replacement (GHR) in these individuals remains unclear.
Objective To assess the effect of GHR on tumour recurrence in patients with NFAs solely treated by surgical removal.
Patients and methods The study involved all patients with NFA who presented to the Department of Endocrinology in Oxford between January 1989 and July 2005 and were treated solely by surgical removal of the tumour. Patients with follow up < 1 year were excluded. Recurrence was diagnosed on the basis of radiological appearances (detectable tumour after gross total removal or regrowth of pre‐existing residue) on regular imaging surveillance.
Results One hundred and thirty patients were included in the study, and were followed up for a mean period of 6·8 ± 4·2 years (median 5·7, range 1·2–17·6). Twenty‐three patients received GHR [16 male, 7 female, mean age at tumour diagnosis 53·7 ± 14·6 years (range 20–80)]. The mean duration of GHR was 4·6 ± 2·5 years (median 5·3, range 0·4–8·7). One hundred and seven subjects did not receive GH therapy [61 male, 46 female, mean age at tumour diagnosis 56·2 ± 14·0 years (range 20–87)]. Tumour regrowth occurred in 38 non‐GH treated subjects (36%) and 8 GHR subjects (35%). Regrowth was detected at a mean of 4·8 ± 2·8 years (range 1–11 years) in the non‐GH treated group, and at 6·5 ± 2·3 years in the GHR group. In the GHR group, recurrence occurred after a mean of 2·9 ± 2·2 years (range 0·4–5·9 years) following commencement of GH treatment. The Cox regression analysis showed that after adjusting for sex, age at tumour diagnosis, cavernous sinus invasion at diagnosis and type of tumour removal (partial or complete based on postoperative scan), GH treatment was not a significant independent predictor of recurrence (P = 0·09; hazard ratio = 0·51; 95% CI, 0·24–1·12).
Conclusion GH replacement in patients with NFA treated by surgery alone is not associated with an increased risk of tumour recurrence.</description><subject>Adenoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Growth Hormone - adverse effects</subject><subject>Growth Hormone - deficiency</subject><subject>Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Hypothalamus. Hypophysis. Epiphysis (diseases)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Pituitary Neoplasms - surgery</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Vertebrates: endocrinology</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc2O0zAUhSMEYsrAKyBvQLBIuP6JkyxYjKqZDlJVNiCWluPYgzuJU2xH074LD4vTVmUJ3vja_s7xtU-WIQwFTuPTtsCUlzkhvCwIQF0ApQ0u9s-yxeXgebYACpAD5-wqexXCFgDKGqqX2RVuCE3bsMh-r-6R17teKj1oF5F1aCejTWVATzb-RG50uZmcinZ01j2gnY2TjdIfkOy0GweJPmzubj6i6LWMukNh7HV_QO0Bhck_6MTZkEwikiGMyh6Zo7F1KklCWnobHtFoUJyGcfKpHTV5r53Sr7MXRvZBvznP19n3u9tvy_t8_XX1ZXmzzhXjHOdtJSvJsWaEt4apWipFjQHTtYZShas2vVSzkrTQKsJwg-uybgxtlYaubAym19n7k-_Oj78mHaIYbFC676XT4xQE503JgPF_ggQYkKZiCaxPoPJjCF4bsfN2SL8mMIg5QrEVc1JiTkrMEYpjhGKfpG_Pd0ztoLu_wnNmCXh3BmRQsjdeOmXDhSMY04bwmft84p5srw__3YBY3m7mKunzk96GqPcXvfSPgle0KsWPzUow3kBTrkHU9A_ousj-</recordid><startdate>200903</startdate><enddate>200903</enddate><creator>Arnold, J. R.</creator><creator>Arnold, D. F.</creator><creator>Marland, A.</creator><creator>Karavitaki, N.</creator><creator>Wass, J. A. H.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>200903</creationdate><title>GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence</title><author>Arnold, J. R. ; Arnold, D. F. ; Marland, A. ; Karavitaki, N. ; Wass, J. A. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4661-b7a7a61e426bf4c8acc3ff0fdbf33c17b640e452b0bc241918589f3bce0d59f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adenoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Growth Hormone - adverse effects</topic><topic>Growth Hormone - deficiency</topic><topic>Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Hypothalamus. Hypophysis. Epiphysis (diseases)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Pituitary Neoplasms - surgery</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arnold, J. R.</creatorcontrib><creatorcontrib>Arnold, D. F.</creatorcontrib><creatorcontrib>Marland, A.</creatorcontrib><creatorcontrib>Karavitaki, N.</creatorcontrib><creatorcontrib>Wass, J. A. H.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arnold, J. R.</au><au>Arnold, D. F.</au><au>Marland, A.</au><au>Karavitaki, N.</au><au>Wass, J. A. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2009-03</date><risdate>2009</risdate><volume>70</volume><issue>3</issue><spage>435</spage><epage>438</epage><pages>435-438</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>Summary
Background Subjects with non‐functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy. The safety of GH replacement (GHR) in these individuals remains unclear.
Objective To assess the effect of GHR on tumour recurrence in patients with NFAs solely treated by surgical removal.
Patients and methods The study involved all patients with NFA who presented to the Department of Endocrinology in Oxford between January 1989 and July 2005 and were treated solely by surgical removal of the tumour. Patients with follow up < 1 year were excluded. Recurrence was diagnosed on the basis of radiological appearances (detectable tumour after gross total removal or regrowth of pre‐existing residue) on regular imaging surveillance.
Results One hundred and thirty patients were included in the study, and were followed up for a mean period of 6·8 ± 4·2 years (median 5·7, range 1·2–17·6). Twenty‐three patients received GHR [16 male, 7 female, mean age at tumour diagnosis 53·7 ± 14·6 years (range 20–80)]. The mean duration of GHR was 4·6 ± 2·5 years (median 5·3, range 0·4–8·7). One hundred and seven subjects did not receive GH therapy [61 male, 46 female, mean age at tumour diagnosis 56·2 ± 14·0 years (range 20–87)]. Tumour regrowth occurred in 38 non‐GH treated subjects (36%) and 8 GHR subjects (35%). Regrowth was detected at a mean of 4·8 ± 2·8 years (range 1–11 years) in the non‐GH treated group, and at 6·5 ± 2·3 years in the GHR group. In the GHR group, recurrence occurred after a mean of 2·9 ± 2·2 years (range 0·4–5·9 years) following commencement of GH treatment. The Cox regression analysis showed that after adjusting for sex, age at tumour diagnosis, cavernous sinus invasion at diagnosis and type of tumour removal (partial or complete based on postoperative scan), GH treatment was not a significant independent predictor of recurrence (P = 0·09; hazard ratio = 0·51; 95% CI, 0·24–1·12).
Conclusion GH replacement in patients with NFA treated by surgery alone is not associated with an increased risk of tumour recurrence.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19236640</pmid><doi>10.1111/j.1365-2265.2008.03391.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2009-03, Vol.70 (3), p.435-438 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66954046 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adenoma - surgery Adult Aged Aged, 80 and over Biological and medical sciences Endocrinopathies Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Growth Hormone - adverse effects Growth Hormone - deficiency Growth Hormone - therapeutic use Humans Hypothalamus. Hypophysis. Epiphysis (diseases) Male Medical sciences Middle Aged Neoplasm Recurrence, Local - epidemiology Non tumoral diseases. Target tissue resistance. Benign neoplasms Pituitary Neoplasms - surgery Regression Analysis Retrospective Studies Risk Factors Vertebrates: endocrinology |
| title | GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T12%3A52%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GH%20replacement%20in%20patients%20with%20non-functioning%20pituitary%20adenoma%20(NFA)%20treated%20solely%20by%20surgery%20is%20not%20associated%20with%20increased%20risk%20of%20tumour%20recurrence&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Arnold,%20J.%20R.&rft.date=2009-03&rft.volume=70&rft.issue=3&rft.spage=435&rft.epage=438&rft.pages=435-438&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1111/j.1365-2265.2008.03391.x&rft_dat=%3Cproquest_cross%3E20402974%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20402974&rft_id=info:pmid/19236640&rfr_iscdi=true |